FDA granted priority review to Zepzelca plus Tecentriq for first-line maintenance in extensive-stage small cell lung cancer.

Regulatory action was based on data from the Phase III IMforte trial, which showed that Zepzelca plus Tecentriq significantly extended both progression-free survival and overall survival in patients ...

The FDA has accepted the application for lurbinectedin in combination with atezolizumab as first-line maintenance for ES-SCLC.

Brian P. Mulherin, MD, shares his key takeaways from the 2025 ASCO Annual Meeting, highlighting significant advancements in SCLC and the challenge of information overload at large conferences.

PharmaMar-partnered Zepzelca (lurbinectedin), for small cell lung cancer. JZP-458 for blood cancers has also been filed and is set for an FDA verdict this year. Combining with GW will create a ...

Detailed price information for Jazz Pharma Plc (JAZZ-Q) from The Globe and Mail including charting and trades.

Detailed price information for Jazz Pharma Plc (JAZZ-Q) from The Globe and Mail including charting and trades.

Keytruda marks the first perioperative anti-PD-1 treatment option for adults with PD-L1–positive resectable locally advanced head and neck squamous cell carcinoma. The FDA has approved Merck’s ...